Robert D. Gordon
Hoffmann-La Roche
19 Papers
627 Citations
Robert D. Gordon is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Transplantation & Mycophenolic acid. The author has an hindex of 17, co-authored 19 publications. Previous affiliations of Robert D. Gordon include Emory University.
Chat about Author
Papers
Daclizumab to prevent rejection after cardiac transplantation.
Ray E. Hershberger,Randall C. Starling,Howard J. Eisen,Claes Håkan Bergh,Robert L. Kormos,Robert B. Love,Adrian B. Van Bakel,Robert D. Gordon,Rina Popat,Louise Cockey,Richard D. Mamelok +10 more
TL;DR: Daclizumab was efficacious as prophylaxis against acute cellular rejection after cardiac transplantation and concurrent or anticipated use of cytolytic therapy with daclIZumab should be avoided.
209
Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients
Reinier M. van Hest,Ron A. A. Mathôt,Mark D. Pescovitz,Robert D. Gordon,Richard D. Mamelok,Teun van Gelder +5 more
TL;DR: Exposure to total MPA, as determined by MPA clearance, significantly increased with increasing renal function, albumin level, and hemoglobin as well as decreasing cyclosporine predose level, which provides an indication for therapeutic drug monitoring as MPA exposure may be altered.
Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration.
Herwig Ulf Meier-Kriesche,Bettina J. Steffen,Alan Hochberg,Robert D. Gordon,Michael N. Liebman,Jonathan A. Morris,Bruce Kaplan +6 more
TL;DR: Continuous use of MMF versus AZA was associated with a protective effect against declining renal function beyond 1 year after transplantation, and continued MMF therapy is protective against long-term deterioration in renal function.
140
Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.
Russell H. Wiesner,Jolene S. Shorr,Bettina J. Steffen,A H. Chu,Robert D. Gordon,John R. Lake +5 more
TL;DR: Outcomes were similar for the cohort with HCV, and MMF triple therapy at discharge was associated with a reduced risk of death, graft loss, acute rejection, and death from infectious complications.
131
Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection.
Herwig Ulf Meier-Kriesche,Bettina J. Steffen,Alan Hochberg,Robert D. Gordon,Michael N. Liebman,Jonathan A. Morris,Bruce Kaplan +6 more
TL;DR: To evaluate the association of long‐term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998 are analyzed.
126